Scilex Holding Company
SCLX
Rank in Stocks
#28102
Scilex Holding Company is a biopharmaceutical enterprise that specializes in... Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
Share Price
$1.74
Last synced: 2026-11-09
Market Cap
$12.24M
Change (1 day)
2.35%
Change (1 year)
-90.26%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Scilex Holding Company (SCLX)
Category
Healthcare
EPS for Scilex Holding Company (SCLX)
EPS as of June 2026 TTM: $-64.88
According to Scilex Holding Company's latest financial reports, its current EPS (TTM) is $-64.88. At the end of 2025 the company had an EPS of $-36.48, a decrease compared to its 2024 EPS of $-19.43.
EPS history for Scilex Holding Company from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-64.88 | 77.85% |
| 2025 | $-36.48 | 87.75% |
| 2024 | $-19.43 | -56.68% |
| 2023 | $-44.85 | 636.45% |
| 2022 | $-6.09 | -73.85% |
| 2021 | $-23.29 | 184,741.27% |
| 2020 | $-0.01 | -99.01% |
| 2019 | $-1.27 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $30.89 | -147.61% |
US
|
|
| $6.60 | -110.17% |
US
|
|
| $5.83 | -108.99% |
US
|
|
| $0.98 | -101.51% |
US
|
|
| $18.54 | -128.58% |
CH
|
Questions about Scilex Holding Company's earnings per share (EPS)
What is Scilex Holding Company's earnings per share (EPS)?
Scilex Holding Company's earnings per share (EPS) over the last twelve months is $-64.88, as of Jun 2026.
What was Scilex Holding Company's earnings per share (EPS) in 2025?
In 2025, Scilex Holding Company's earnings per share (EPS) was $-36.48, compared with $-19.43 in 2024.
How has Scilex Holding Company's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Scilex Holding Company's earnings per share (EPS) was highest in 2020 ($-0.01) and lowest in 2023 ($-44.85).
How does Scilex Holding Company's earnings per share (EPS) compare with similar companies?
Scilex Holding Company's earnings per share (EPS) ($-64.88) is lower than that of all 5 similar companies listed above. The highest among them is Eli Lilly and Company, with $30.89.